TESARO Pioneers Summit - ppt download
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial - Mirza - 2023 - Cancer - Wiley Online Library
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib in Patients With Newly Diagnosed Advanced Ovarian BRCAm Cancer: A Post Hoc Analysis of the PRIMA/ENGOT-OV26/GOG-3012 T
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer | PPT
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Treatment and Maintenance Therapy in Advanced Ovarian Cancer | VuMedi
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
PARP Inhibitors. - ppt download
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Efficacy of Niraparib by Timing of Surgery and Residual Disease: a Post Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-301
Zejula (niraparib) com resultados positivos como terapêutica de primeira linha | Netfarma
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
CME; Niraparib, Olaparib, bevacizumab, PRIMA trial, PAOLO-1
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Efficacy | ZEJULA (niraparib) for HCPs
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
